Author name: Leonardo Arias

MMI won FDA approval to study robotic surgery for Alzheimer’s disease. Elsewhere, SS Innovations’ CEO performed remote bypass surgery with a new console, and Procept BioRobotics’ Q3 revenue rose 43%.

The Senate overcame a key procedural hurdle on Sunday after eight Democrats broke with their party to back a measure freeing the government from the longest funding lapse in history.

The White Houes may have struck a deal with Eli Lilly and Novo Nordisk last week to lower the costs of their weight loss drugs for patients, but knockoff versions of Zepbound and Wegovy still permeate the obesity market.

Ionis is planning a supplemental submission by the end of the year to expand Tryngolza into severe hypertriglyceridemia. If granted, William Blair expects the antisense drug to be “transformational” for this indication.

MeiraGTx Holdings is licensing a genetic eye disease medicine to Eli Lilly in a deal worth up to $475 million.

Como cabe suponer, una infidelidad es un acontecimiento doloroso y muy desestabilizador para cualquier pareja que llegue a padecerlo. Es un suceso que produce una ruptura en la confianza, en el acuerdo tácito afectivo que se da sin decirlo. La autoestima y la percepción de la relaci&oa …

The deal is done. What happens next for Pfizer and Metsera—and Novo?

Multiple analyst firms were impressed by the Phase III data, which showed that Merck’s oral PCSK9 inhibitor can lower low-density lipoprotein cholesterol by more than 55% after 24 weeks.

Eli Lilly has been on a dealmaking spree this year, with a few deals worth $1 billion or more. Aside from SangeneBio, these include SiteOne, Verve and Scorpion.

The cholesterol-lowering drug is part of a suite of medicines that also includes MariTide and that Amgen Chief Medical Officer Paul Burton hopes will make the company the “undisputed leader in the management of cardiometabolic risk for patients” by 2030.